A new report is peeling back the curtain on Chinese pharmaceutical innovation, assessing which companies are best at driving the drug development that’s captured the attention of pharmaceutical executives and investors worldwide.
On Sunday, IDEA Pharma and parent company SAI MedPartners released their inaugural China Pharmaceutical Innovation and Invention Index. The report joins a global pharmaceutical ranking that IDEA produces every spring.
The rankings were chosen from a list of 50 companies around China. The report ranks the top companies for invention — namely, which companies are developing new medicines that matter and use novel science — and innovation, which assesses how these companies are developing and launching medicines. Research spending, international patent filings, and drug approvals all factor into a company’s standing.
Continue to STAT+ to read the full story…
STAT Pharma: The science and business of new drug development
Leave a Reply